|
October
28, 2002
Current Technology Retains Regulatory
Consultant To Assist In ETG Hair Loss Treatment Application
To The FDA |
|
Reprint with
permission from Current Technology
Vancouver BC,
October 28, 2002 - Current Technology Corporation
(OTCBB: CRTCF), developer of the ElectroTrichoGenesis (ETG) hair
loss
treatment device, today announced that it has retained regulatory
consultant, Judi Weissinger, Ph.D., to assist the company with its
application to the United States Food and Drug Administration (FDA).
Dr. Weissinger is president of Weissinger Solutions, Inc (WSI). The
company provides strategic guidance of global regulatory
applications
for pharmaceutical, medical device, and biological products,
preparing and reviewing regulatory submissions to ensure they meet
filing and acceptability requirements. Melding science and
regulations, WSI develops strategies designed to obtain rapid
approval for entry into the marketplace in the United States.
Prior to founding WSI, Dr. Weissinger was Vice President of
Regulatory Affairs and Worldwide Quality at RPR Gencell (formerly
Applied Immune Sciences) and Director of Non-clinical Regulatory
Affairs and Compliance at Glaxo Research Institute. She also held a
number of senior positions at the Food and Drug Administration,
including those of Head of Pharmacology/Toxicology at the Center for
Drug Evaluation and Research, and Acting Deputy Director of the
Office of Science and Technology in the Center for Devices and
Radiological Health. While at the FDA, Dr. Weissinger was involved
in
the interpretation and implementation of the new device regulation
revisions. Dr. Weissinger earned a B.Sc. in Chemistry/Chemical
Engineering from the University of Iowa and a Ph.D. in Medical
Science/Pharmacology from the University of New Mexico.
"I have served over 100 satisfied clients in the last six
years,"
says Dr. Weissinger. "All regulatory requests for marketing and
advisory committee presentations developed and coordinated by WSI
have been successful."
The ETG device is approved for use in Europe where it has both Class
II-A approval and the CE Mark certification. In addition, the device
is approved in Canada (Health Protection Branch), Mexico (Secretaria
de Salud), New Zealand (Ministry of Health) and Australia
(Therapeutic Goods Administration).
The patented, electro-therapeutic ETG device provides a clinically
proven medical treatment for excessive hair loss (common baldness).
ETG treatments have also proven to have encouraging results on women
with breast cancer undergoing chemotherapy, as reported in a recent
issue of the peer-reviewed journal, Psycho-Oncology (May/June 2002).
ETG treatment centers are presently located in several countries
around the world.
For further information, please see http://www.etgtreatment.com.
Research
Forum
The above
is a press release from Current Technology, Canada.
|
